As artificial intelligence (AI) continues to make significant advances, the leaders of clinical trials should not underestimate its capabilities for improving patient recruitment, retention
Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo